ÂÜÀòÂÒÂ×

Tina Flatau possesses extensive experience in the biopharmaceutical sector, currently serving as an NHS HRA Ethics Committee Member and Chief Business Officer at Sixfold Bioscience. With a strong leadership role as Chair of the Board of Trustees and advisory in Action Duchenne's Research Committee, Tina has contributed significantly to the field. Past positions include Managing Directorships at MEDANNEX LIMITED, OncoBioPharm Ltd, and aTen Therapeutics Ltd, alongside a VP role at Prosensa Therapeutics, where Tina focused on RNA modulation for rare neuromuscular diseases. Tina's background is supported by a PhD in Pharmaceutics and Pharmacology from King's College London and a B Pharm from Chelsea School of Pharmacy.